

Stereoselective synthesis of a conformationally restricted β -hydroxy- γ -amino acid


Dong Xiao,^a Patrick J. Carroll,^a Scott C. Mayer,^b Amy J. Pfizenmayer^a and Madeleine M. Joullie^{a,*}

^a Department of Chemistry, University of Pennsylvania, Philadelphia, PA 19104-6323, USA

^b Wyeth-Ayerst Research, 865 Ridge Road, Monmouth Junction, NJ 08852, USA

Abstract: β -Hydroxy- γ -amino acids are a class of non-proteinogenic amino acids present in many important biologically active natural products. In conjunction with our research on didemnins, we designed and synthesized a sterically constrained β -hydroxy- γ -amino acid in which the requisite carboxyl, hydroxyl and amino groups are positioned on a conformationally stable 6-membered ring. © 1997 Elsevier Science Ltd


β -Hydroxy- γ -amino acids are a class of non-proteinogenic amino acids present in many important biologically active natural products.¹ The representative member, statine 1,² is the key amino acid in the acidic protease inhibitor pepstatine. Statine has been shown to mimic the transition state of the enzymatic hydrolysis of the scissile dipeptide bond³ and this concept eventually led to the development of some anti-HIV drugs on the market. Another interesting β -hydroxy- γ -amino acid, isostatine 2,⁴ is a component of the didemnins, a family of cyclodepsipeptides which exhibits a broad spectrum of biological activities. In conjunction with our research on didemnins, we designed a β -hydroxy- γ -amino acid 3 in which the requisite hydroxyl and amino groups are positioned on a conformationally stable 6-membered ring.⁵ Conformational constraint of amino acids is an important tool to improve the properties of bioactive peptidal agents.^{6–8} This approach also proves valuable in investigating the bioactive conformation of drugs and receptors.^{9–11}




We now report the synthesis of an enantiomerically pure cyclohexane β -hydroxy- γ -amino acid 3 which has evaded our previous synthetic endeavors.¹² The particular (*S,S,S*)-isomer was designed by molecular modelling studies.⁵ Synthesis of the designed cyclohexane amino acid began with an auxiliary type Diels–Alder reaction. Thus, the camphorsultam derived dienophile 4¹³ was reacted with 1-acetoxy-1,3-diene in 4 M lithium perchlorate in ether.¹⁴ Two products were obtained in a ratio of 96:4, in which the desired *endo* product 5 predominated. No *exo* product was detected but a 1,3-regioisomer 6 was isolated and both structures were identified with the aid of X-ray crystal analysis (Equation 1).

* Corresponding author. Email: mjoullie@sas.upenn.edu

Equation 1:



After the asymmetric Diels-Alder reaction was completed, the major product **5** was hydrolyzed to give the intermediate hydroxy acid **7** in nearly quantitative yield. Introduction of the amino group was envisioned by an azide displacement at the γ -position, which in turn could be functionalized by iodolactonization. Although initial attempts employing I₂-Na₂CO₃ or NaH failed, we later found that iodonium biscollidine perchlorate¹⁵ effected the desired transformation and gave iodolactone **8** in 70% yield. The iodine was removed under radical conditions using tris(trimethylsilyl)silane and the β -hydroxyl group in the resulting hydroxylactone **9** was then protected as its benzyl ether **10** in 87% yield. This lactone, **10**, was subjected to transesterification with methanol and K₂CO₃ to free the γ -hydroxyl group. However, two problems were encountered. Firstly, very dilute K₂CO₃ was used to prevent the epimerization of the ester, but these conditions resulted in incomplete methanolysis. Secondly, the resulting hydroxyester was unstable on silica gel and readily cyclized to the precursor lactone. Therefore, we carried the intermediate with a small amount of starting material through the next two steps without purification. Inversion of the γ -hydroxyl group with azide was the next step. Unfortunately, inversion of the γ -hydroxyl group using DPPA¹⁶ or Zn(N₃)₂Py₂¹⁷ as azide sources, under Mitsunobu conditions, did not afford a product. The mesylate was also not effectively displaced by azide ion even at elevated temperature. Eventually, the triflate derivative **11** afforded a mixture of the desired azide **12** and an elimination product **13** (Scheme 1).



Scheme 1.


Table 1. Optimization of the azidation reaction conditions

Nucleophile	Solvent	Selectivity (12:13)	yield (12+13) ^a
NaN ₃	DMF	4:1	56% + 14%
NaN ₃	DMF-MeCN	4.5:1	33% + 7%
Zn(N ₃) ₂ Py ₂	DMF	no reaction	-----
Bu ₄ NN ₃	C ₆ H ₆	13 only	0% + 60%
TMSN ₃	MeCN	complex mixture	-----
TMGN ₃	CH ₂ Cl ₂	7:1	62% + 7.5%

^a based on the recovered starting material over 3 steps.

Considerable efforts were directed to optimize the azidation reaction conditions and the results are summarized in Table 1. The alkaline metal azides such as NaN₃, LiN₃ and TMSN₃-CsF¹⁸ in DMF all gave the same results (only the representative results with NaN₃ are shown in Table 1). The azide concentration proved to be a critical factor because at lower concentration less product from elimination was formed. Although lowering the polarity of the solvent was thought to yield less eliminated product¹⁹ as in the case of 1:1 DMF:MeCN, this protocol also retarded the reaction rate and resulted in a low overall yield. When the reaction was run in benzene under phase transfer conditions using tetrabutylammonium chloride and sodium azide,¹⁹ only **13** was obtained. Other azides also proved unsatisfactory. Eventually, when buffered tetramethylguanidinium azide²⁰ was used, the desired product **12** was isolated in 62% yield, based on the recovered starting material, along with 7.5% elimination product **13**.

With the functionalities and desired stereochemistries secured, the methyl ester **12** was hydrolyzed to afford the corresponding free acid **14**, whose relative configuration was confirmed by X-ray crystal analysis. The azido acid **14** was then hydrogenated to afford the targeted amino acid **3** in zwitterionic form (Scheme 2).²¹



Scheme 2.

Acknowledgements

We gratefully acknowledge the National Institute of Health (CA 40081) and the University of Pennsylvania for financial support. We also thank Dr G. T. Furst, Dr R. Kohli and Mr J. Dykins of the University of Pennsylvania Analytical Facility for their expert technical assistance.

References

- Castejón, P.; Moyano, A.; Pericàs, M. A.; Riera, A. *Tetrahedron* **1996**, *52*, 7063.
- Umezawa, H.; Aiyagi, T.; Morishima, H.; Matsuzaki, M.; Hamada, H.; Takeuchi, T. *J. Antibiot.* **1970**, *23*, 259.
- Rich, D. H. *J. Med. Chem.* **1985**, *28*, 263.
- Rinehart, K. L.; Kishore, V.; Nagarajan, S.; Lake, R. J.; Gloh, J. B.; Bozich, F. A.; Li, K.-M.; Maleczka, J. R. E.; Todsén, W. L.; Munro, M. H. G.; Sullins, D. W.; Sakai, R. *J. Am. Chem. Soc.* **1987**, *109*, 6846.
- Mayer, S. C.; Pfizenmayer, A. J.; Joullié, M. M. *J. Org. Chem.* **1996**, *61*, 1655.
- Liskamp, R. M. *Recl. Trav. Chim. Pays-Bas* **1994**, *113*, 1.
- Gante, J. *Angew. Chem. Int. Ed. Engl.* **1994**, *33*, 1699.

8. Giannis, A.; Kolter, T. *Angew. Chem. Int. Ed. Engl.* **1993**, *32*, 1244.
9. Szewczuk, Z.; Rebholz, K. L.; Rich, D. H. *Int. J. Pept. Protein Res.* **1992**, *40*, 233.
10. Shimamoto, K.; Ohfuné, Y. *J. Med. Chem.* **1996**, *39*, 407.
11. Shao, H.; Lee, C.-W.; Zhu, Q.; Gantzel, P.; Goodman, M. *Angew. Chem. Int. Ed. Engl.* **1996**, *35*, 90.
12. Mayer, S. C.; Pfizenmayer, A. J.; Cordova, R.; Li, W.-R.; Joullié, M. M. *Tetrahedron: Asymmetry* **1994**, *5*, 519.
13. Ho, G.-J.; Mathre, D. J. *J. Org. Chem.* **1995**, *60*, 2271.
14. Grieco, P. A.; Nunes, J. J.; Gaul, M. D. *J. Am. Chem. Soc.* **1990**, *112*, 4595.
15. Lemieux, R. U.; Morgan, A. R. *Can. J. Chem.* **1965**, *43*, 2190.
16. Lal, B.; Pramanik, B. N.; Manhas, M. S.; Bose, A. K. *Tetrahedron Lett.* **1977**, 1977.
17. Viaud, M. C.; Rollin, P. *Synthesis* **1990**, 130.
18. Sato, T.; Otera, J. *Synlett* **1995**, 336.
19. Vatéle, J.-M.; Hanessian, S. *Tetrahedron* **1996**, *52*, 10557.
20. Papa, A. *J. Org. Chem.* **1966**, *31*, 1426.
21. All new compounds were characterized by ¹H and ¹³C NMR, IR and HRMS. Data for compound **3**: off-white powder, mp: 242°C (dec.); [α]_D=+72.5 (c=1.22, H₂O); IR (KBr), 3380, 3306, 2965 (broad), 1580 cm⁻¹; ¹H NMR (D₂O): δ 3.54 (1H, b), 3.29 (1H, b), 2.77 (1H, b), 2.26-1.97 (2H, m), 1.56 (1H, b), 1.38-1.23 (3H, m); ¹³C NMR: δ 183.70, 74.59, 56.11, 48.26, 31.31, 29.51, 23.17; HRMS (EI): calcd for C₇H₁₄NO₃ 160.0973 (MH), found 160.0967.

(Received in USA 7 August 1997)